1. Home
  2. RVSN vs SNGX Comparison

RVSN vs SNGX Comparison

Compare RVSN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

N/A

Current Price

$2.38

Market Cap

7.9M

Sector

N/A

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$0.33

Market Cap

7.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RVSN
SNGX
Founded
2016
1987
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.6M
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
RVSN
SNGX
Price
$2.38
$0.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $1.38
AVG Volume (30 Days)
20.9K
★ 104.2K
Earning Date
08-26-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.03
EPS
★ N/A
N/A
Revenue
N/A
★ $119,371.00
Revenue This Year
$169.00
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.31
52 Week High
$9.39
$3.39

Technical Indicators

Market Signals
Indicator
RVSN
SNGX
Relative Strength Index (RSI) 32.45 35.24
Support Level N/A $0.32
Resistance Level $3.52 $0.82
Average True Range (ATR) 0.26 0.02
MACD -0.03 0.00
Stochastic Oscillator 0.89 29.59

Price Performance

Historical Comparison
RVSN
SNGX

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: